Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 71 publications
Enzalutamide Monotherapy for the Treatment of Prostate Cancer with High-Risk Biochemical Recurrence: EMBARK Secondary End Points: Erratum.
Journal: The Journal of urology
Published: July 09, 2026
Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer.
Journal: Journal for immunotherapy of cancer
Published: April 24, 2026
Real-world clinical outcomes of patients with localized prostate cancer treated with radical prostatectomy in SEER-Medicare.
Journal: Journal of comparative effectiveness research
Published: February 16, 2026
Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Undergoing Radical Prostatectomy Across Different Risk Stratifications in the United States.
Journal: ClinicoEconomics and outcomes research : CEOR
Published: January 07, 2026
Treatment and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer by Race, Initial Diagnosis, and Family History: Results From the TRUMPET Registry.
Journal: Clinical genitourinary cancer
Published: December 11, 2025
Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points.
Journal: The Journal of urology
Published: December 05, 2025
Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS Registry.
Journal: JCO precision oncology
Published: September 19, 2025
Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review.
Journal: Future oncology (London, England)
Published: June 30, 2025
Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies.
Journal: Future oncology (London, England)
Published: August 20, 2024
North American study and meta-analysis evaluating performance of Bladder EpiCheck®, a FDA cleared test, in non-muscle invasive bladder cancer recurrence.
Journal: Bladder cancer (Amsterdam, Netherlands)
Published: July 22, 2024
Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2).
Journal: Prostate cancer and prostatic diseases
Published: June 25, 2024
Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2).
Journal: Prostate cancer and prostatic diseases
Published: June 25, 2024
Last Updated: 09/26/2026